![Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer | Anticancer Research Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/42/8/3889/F2.large.jpg)
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer | Anticancer Research
O-1: NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with mPDAC: additional results from NAPOLI 3 on Vimeo
![First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study - ScienceDirect First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921001957-ga1.jpg)
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study - ScienceDirect
![Transport pathway of irinotecan. Notes: A prodrug, irinotecan, is moved... | Download Scientific Diagram Transport pathway of irinotecan. Notes: A prodrug, irinotecan, is moved... | Download Scientific Diagram](https://www.researchgate.net/publication/314126251/figure/fig1/AS:467088386072576@1488373957147/Transport-pathway-of-irinotecan-Notes-A-prodrug-irinotecan-is-moved-into-hepatic.png)
Transport pathway of irinotecan. Notes: A prodrug, irinotecan, is moved... | Download Scientific Diagram
![MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer | Future Oncology MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.15.333/asset/images/medium/figure1.gif)
MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer | Future Oncology
![Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer | ACS Nano Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer | ACS Nano](https://pubs.acs.org/cms/10.1021/acsnano.8b06164/asset/images/large/nn-2018-06164w_0007.jpeg)
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer | ACS Nano
![Cancers | Free Full-Text | Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect Cancers | Free Full-Text | Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect](https://www.mdpi.com/cancers/cancers-15-05588/article_deploy/html/images/cancers-15-05588-g001.png)
Cancers | Free Full-Text | Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect
![Pharmacokinetic profile of nal-IRI and free irinotecan. A, plasma and... | Download Scientific Diagram Pharmacokinetic profile of nal-IRI and free irinotecan. A, plasma and... | Download Scientific Diagram](https://www.researchgate.net/publication/273000082/figure/fig2/AS:667813295427587@1536230505461/Pharmacokinetic-profile-of-nal-IRI-and-free-irinotecan-A-plasma-and-tumor-PK-of-nal-IRI.png)
Pharmacokinetic profile of nal-IRI and free irinotecan. A, plasma and... | Download Scientific Diagram
![Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/public/attachments/21b9b29c-ad57-4fb3-899e-e7d55c143823/large/image1.png)
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology
![Ein „unmet medical need“ – nur zögerliche Verbesserung der Outcomes - Onkologie - Universimed - Medizin im Fokus Ein „unmet medical need“ – nur zögerliche Verbesserung der Outcomes - Onkologie - Universimed - Medizin im Fokus](https://www.universimed.com/custom/img/files/files_data_Zeitungen_2016_Jatros_Onko_1606_Weblinks_seite84_2.jpg)
Ein „unmet medical need“ – nur zögerliche Verbesserung der Outcomes - Onkologie - Universimed - Medizin im Fokus
![Molecules | Free Full-Text | Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment Molecules | Free Full-Text | Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment](https://www.mdpi.com/molecules/molecules-25-02614/article_deploy/html/images/molecules-25-02614-g001.png)
Molecules | Free Full-Text | Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
![Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study | BMC Cancer | Full Text Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-021-08887-1/MediaObjects/12885_2021_8887_Fig2_HTML.png)
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study | BMC Cancer | Full Text
![Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial - The Lancet Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/a7d96e41-3ed3-43f4-aeb4-a4bcbd10d264/gr1.gif)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial - The Lancet
![Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer - Brendel - 2021 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer - Brendel - 2021 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/41ce0f49-5f45-4554-8c20-d1ac13cac9e5/psp412725-fig-0001-m.jpg)
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer - Brendel - 2021 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
![Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer | ACS Nano Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer | ACS Nano](https://pubs.acs.org/cms/10.1021/acsnano.8b06164/asset/images/large/nn-2018-06164w_0001.jpeg)